Swedbank AB Has $25.29 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN

Swedbank AB raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 466,943 shares of the biotechnology company’s stock after acquiring an additional 35,000 shares during the period. Swedbank AB’s holdings in BioMarin Pharmaceutical were worth $25,290,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Dodge & Cox lifted its holdings in shares of BioMarin Pharmaceutical by 1.0% in the 2nd quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company’s stock worth $830,504,000 after purchasing an additional 153,070 shares in the last quarter. Viking Global Investors LP increased its stake in BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC raised its holdings in BioMarin Pharmaceutical by 90.7% during the second quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after buying an additional 2,654,768 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of BioMarin Pharmaceutical by 1.3% in the second quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock valued at $190,417,000 after buying an additional 43,185 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of BioMarin Pharmaceutical during the second quarter valued at about $112,352,000. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $59.94 on Friday. The company has a market capitalization of $11.52 billion, a PE ratio of 22.53, a PEG ratio of 1.00 and a beta of 0.30. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average price is $54.26 and its 200-day moving average price is $55.73. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $73.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The business had revenue of $776.13 million for the quarter, compared to analysts’ expectations of $782.42 million. During the same period in the previous year, the business posted $0.91 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analyst Ratings Changes

BMRN has been the topic of a number of analyst reports. Stifel Nicolaus restated a “hold” rating and issued a $61.00 target price (down previously from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. HC Wainwright boosted their price objective on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday. Sanford C. Bernstein lowered their price objective on BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a research note on Monday, November 3rd. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Raymond James Financial assumed coverage on BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 price target for the company. Sixteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $89.70.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.